WEBSITE BSE:539268 NSE : SYNGENE 06 Sep, 16:03
Market Cap ₹36214 Cr.
Stock P/E 73.5
P/B 8.5
Current Price ₹899.7
Book Value ₹ 105.9
Face Value 10
52W High ₹924.3
Dividend Yield 0.14%
52W Low ₹ 608
Syngene International Ltd is a contract research enterprise. The Company is engaged in providing agreement research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies. Its offerings consist of discovery chemistry and biology offerings, toxicology, pharmaceutical development, technique improvement/manufacture of intermediates, active pharmaceutical ingredients and bio-therapeutics. Its services consists of integrated, discovery and development offerings for novel molecular entities (NMEs) across commercial sectors, such as pharmaceutical, biopharmaceutical and biotechnology, amongst others. It specializes in undertaking discovery (from hit to candidate selection), development (together with pre-scientific and clinical studies, analytical and bio-analytical evaluation, and stability studies) and manufacturing (scale-up, pre-clinical and manufacturing components). It serves customers ranging from multinational agencies to start-ups.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
#(Fig in Cr.) | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 758 | 645 | 768 | 786 | 994 | 808 | 910 | 854 | 917 | 790 |
Other Income | 24 | 16 | 15 | 17 | 23 | 24 | 22 | 29 | 16 | 18 |
Total Income | 782 | 660 | 784 | 803 | 1017 | 832 | 932 | 883 | 933 | 808 |
Total Expenditure | 517 | 472 | 552 | 555 | 680 | 596 | 656 | 622 | 600 | 620 |
Operating Profit | 265 | 188 | 232 | 248 | 337 | 236 | 276 | 261 | 333 | 188 |
Interest | 6 | 9 | 12 | 14 | 10 | 11 | 13 | 11 | 13 | 12 |
Depreciation | 80 | 86 | 90 | 95 | 96 | 102 | 105 | 108 | 111 | 107 |
Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -7 | -4 | 0 | 32 |
Profit Before Tax | 179 | 93 | 130 | 140 | 231 | 123 | 151 | 138 | 209 | 101 |
Provision for Tax | 31 | 19 | 28 | 30 | 52 | 30 | 34 | 27 | 20 | 26 |
Profit After Tax | 148 | 74 | 102 | 110 | 179 | 93 | 117 | 112 | 189 | 76 |
Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit After Adjustments | 148 | 74 | 102 | 110 | 179 | 93 | 117 | 112 | 189 | 76 |
Adjusted Earnings Per Share | 3.7 | 1.8 | 2.5 | 2.7 | 4.5 | 2.3 | 2.9 | 2.8 | 4.7 | 1.9 |
#(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
---|---|---|---|---|---|---|---|---|
Net Sales | 1423 | 1826 | 2012 | 2184 | 2604 | 3193 | 3489 | 3471 |
Other Income | 136 | 76 | 96 | 83 | 108 | 73 | 91 | 85 |
Total Income | 1559 | 1902 | 2108 | 2268 | 2713 | 3266 | 3579 | 3556 |
Total Expenditure | 1033 | 1290 | 1409 | 1531 | 1864 | 2260 | 2474 | 2498 |
Operating Profit | 527 | 612 | 700 | 736 | 849 | 1005 | 1105 | 1058 |
Interest | 23 | 32 | 35 | 28 | 24 | 45 | 47 | 49 |
Depreciation | 131 | 164 | 219 | 275 | 310 | 367 | 426 | 431 |
Exceptional Income / Expenses | 0 | 0 | 71 | 35 | -31 | 0 | -11 | 21 |
Profit Before Tax | 373 | 415 | 517 | 469 | 484 | 594 | 621 | 599 |
Provision for Tax | 67 | 84 | 105 | 64 | 89 | 129 | 111 | 107 |
Profit After Tax | 305 | 332 | 412 | 405 | 396 | 464 | 510 | 494 |
Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit After Adjustments | 305 | 332 | 412 | 405 | 396 | 464 | 510 | 494 |
Adjusted Earnings Per Share | 7.6 | 8.3 | 10.3 | 10.1 | 9.9 | 11.6 | 12.7 | 12.3 |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Sales CAGR | 9% | 17% | 14% | 0% |
Operating Profit CAGR | 10% | 15% | 13% | 0% |
PAT CAGR | 10% | 8% | 9% | 0% |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Share Price CAGR | 7% | 13% | 23% | NA% |
ROE Average | 13% | 13% | 15% | 16% |
ROCE Average | 16% | 15% | 16% | 16% |
#(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|
Shareholder's Funds | 1720 | 1968 | 2176 | 2821 | 3298 | 3618 | 4258 |
Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Borrowings | 586 | 347 | 0 | 512 | 532 | 489 | 100 |
Other Non-Current Liabilities | 27 | 168 | 325 | 327 | 440 | 466 | 609 |
Total Current Liabilities | 784 | 1129 | 1539 | 1133 | 1229 | 1188 | 1144 |
Total Liabilities | 3117 | 3612 | 4040 | 4794 | 5498 | 5761 | 6111 |
Fixed Assets | 1030 | 1337 | 1984 | 2163 | 2354 | 2619 | 2809 |
Other Non-Current Assets | 366 | 511 | 444 | 824 | 938 | 717 | 1343 |
Total Current Assets | 1720 | 1764 | 1613 | 1807 | 2206 | 2425 | 1959 |
Total Assets | 3117 | 3612 | 4040 | 4794 | 5498 | 5761 | 6111 |
#(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|
Opening Cash & Cash Equivalents | 235 | 253 | 165 | 193 | 323 | 262 | 90 |
Cash Flow from Operating Activities | 446 | 630 | 677 | 701 | 581 | 824 | 1042 |
Cash Flow from Investing Activities | -349 | -647 | -428 | -628 | -612 | -656 | -496 |
Cash Flow from Financing Activities | -79 | -72 | -226 | 58 | -31 | -343 | -551 |
Net Cash Inflow / Outflow | 18 | -89 | 23 | 131 | -62 | -175 | -5 |
Closing Cash & Cash Equivalent | 253 | 165 | 193 | 323 | 262 | 90 | 86 |
# | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|
Earnings Per Share (Rs) | 7.64 | 8.29 | 10.3 | 10.12 | 9.88 | 11.57 | 12.69 |
CEPS(Rs) | 10.92 | 12.4 | 15.79 | 16.99 | 17.6 | 20.7 | 23.28 |
DPS(Rs) | 1 | 0.5 | 0 | 0 | 1 | 1.25 | 1.25 |
Book NAV/Share(Rs) | 42.31 | 48.51 | 53.42 | 68.61 | 80.09 | 88.51 | 104.19 |
Core EBITDA Margin(%) | 27.44 | 29.34 | 29.99 | 29.9 | 28.43 | 29.18 | 29.05 |
EBIT Margin(%) | 27.77 | 24.52 | 27.41 | 22.75 | 19.53 | 19.98 | 19.13 |
Pre Tax Margin(%) | 26.18 | 22.75 | 25.69 | 21.48 | 18.6 | 18.57 | 17.78 |
PAT Margin (%) | 21.46 | 18.16 | 20.48 | 18.54 | 15.2 | 14.53 | 14.6 |
Cash Profit Margin (%) | 30.69 | 27.16 | 31.38 | 31.1 | 27.09 | 25.99 | 26.8 |
ROA(%) | 9.8 | 9.86 | 10.77 | 9.17 | 7.69 | 8.25 | 8.59 |
ROE(%) | 18.05 | 18.26 | 20.21 | 16.59 | 13.29 | 13.73 | 13.18 |
ROCE(%) | 15.76 | 16.98 | 19.6 | 15.4 | 13.24 | 15.43 | 15.55 |
Receivable days | 68.43 | 60.53 | 66.84 | 73.02 | 68.92 | 59.21 | 50.73 |
Inventory Days | 22.06 | 12.94 | 6.22 | 7.09 | 16.75 | 29.24 | 29.85 |
Payable days | -5502.04 | 2997.21 | 0 | -3357.42 | -4008.24 | -2132.64 | 1652.8 |
PER(x) | 38.56 | 35.46 | 23.45 | 53.68 | 60.44 | 51.39 | 55.31 |
Price/Book(x) | 6.96 | 6.06 | 4.52 | 7.92 | 7.45 | 6.72 | 6.73 |
Dividend Yield(%) | 0.17 | 0.09 | 0 | 0 | 0.17 | 0.21 | 0.18 |
EV/Net Sales(x) | 8.15 | 6.64 | 5 | 10.01 | 9.29 | 7.49 | 7.97 |
EV/Core EBITDA(x) | 22.02 | 19.81 | 14.39 | 29.69 | 28.5 | 23.78 | 25.15 |
Net Sales Growth(%) | 0 | 28.28 | 10.2 | 8.57 | 19.22 | 22.61 | 9.26 |
EBIT Growth(%) | 0 | 13.28 | 23.19 | -9.9 | 2.33 | 25.62 | 4.57 |
PAT Growth(%) | 0 | 8.58 | 24.28 | -1.75 | -2.25 | 17.33 | 9.82 |
EPS Growth(%) | 0 | 8.58 | 24.28 | -1.75 | -2.44 | 17.16 | 9.66 |
Debt/Equity(x) | 0.47 | 0.41 | 0.32 | 0.28 | 0.25 | 0.16 | 0.03 |
Current Ratio(x) | 2.2 | 1.56 | 1.05 | 1.59 | 1.8 | 2.04 | 1.71 |
Quick Ratio(x) | 2.13 | 1.54 | 1.03 | 1.55 | 1.65 | 1.76 | 1.52 |
Interest Cover(x) | 17.41 | 13.86 | 15.94 | 17.94 | 21.1 | 14.13 | 14.15 |
Total Debt/Mcap(x) | 0.07 | 0.07 | 0.07 | 0.04 | 0.03 | 0.02 | 0.01 |
# | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 70.41 | 70.29 | 64.86 | 64.86 | 54.88 | 54.8 | 54.79 | 54.79 | 54.79 | 54.72 |
FII | 13.67 | 14.12 | 16.77 | 16.85 | 23.28 | 23.19 | 23.55 | 21.2 | 20.92 | 20.63 |
DII | 4.43 | 4.21 | 6.77 | 7.04 | 10.73 | 11.19 | 11.7 | 14.62 | 15.79 | 16.78 |
Public | 11.49 | 11.38 | 11.6 | 11.25 | 11.1 | 10.82 | 9.95 | 9.38 | 8.49 | 7.86 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
# | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 28.22 | 28.22 | 26.04 | 26.04 | 22.03 | 22.03 | 22.03 | 22.03 | 22.03 | 22.03 |
FII | 5.48 | 5.67 | 6.73 | 6.76 | 9.35 | 9.32 | 9.47 | 8.52 | 8.41 | 8.3 |
DII | 1.78 | 1.69 | 2.72 | 2.83 | 4.31 | 4.5 | 4.7 | 5.88 | 6.35 | 6.76 |
Public | 4.6 | 4.57 | 4.65 | 4.52 | 4.46 | 4.35 | 4 | 3.77 | 3.42 | 3.16 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 40.08 | 40.14 | 40.14 | 40.14 | 40.14 | 40.2 | 40.2 | 40.2 | 40.2 | 40.25 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
You May Also Know About